Results 111 to 120 of about 19,579 (254)

Policy‐induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia [PDF]

, 2019
Anat Fisher, Greg Carney, Ken Bassett, Malcolm Maclure, Colin R. Dormuth   +4 more
openalex   +1 more source

Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection‐related mortality remains a significant concern for patients' overall survival (OS). Methods This Swedish, population‐based study examined incidence of infections and OS in
Ingrid Glimelius, Love Tätting, Jonatan Freilich, M. Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurður Y. Kristinsson   +6 more
wiley   +1 more source

Cardiovascular Diseases and Pharmacoepidemiology : Present and Future

, 2001
Nobutaka Doba
openalex   +2 more sources

Active Safety Surveillance Using Real‐World Evidence (ASSURE) Implementation: Transparent and Reproducible Real‐World Evidence Standardized Framework to Support Safety Signal Evaluation

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose To summarize experience with Johnson & Johnson's novel Active Safety Surveillance Using Real‐world Evidence (ASSURE) program for producing efficient, transparent, applicable, and impactful RWE to support routine pharmacovigilance processes.
Kevin Haynes, Jenna Reps, Jill Hardin, Eva‐Maria Didden, James Gilbert, Joel Swerdel, Justin Bohn, Mitchell M. Conover, Amir Sarayani, Anthony G. Sena, Emily Yost, Valerie van Baalen, Kourtney Davis, Patrick Ryan, Martijn Schuemie   +14 more
wiley   +1 more source

Instrumental Variable Analyses in Pharmacoepidemiology: What Target Trials Do We Emulate? [PDF]

, 2017
Sonja A. Swanson
openalex   +1 more source

Case-Only Designs in Pharmacoepidemiology: A Systematic Review

, 2012
Sandra Nordmann, Lucie Biard, Philippe Ravaud, Marina Esposito‐Farèse, Florence Tubach   +4 more
openalex   +2 more sources

Drug–Drug Interaction Signals for Major Bleeding in Nursing Home Residents: High‐Throughput Screening of Clopidogrel and Oral Anticoagulants

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose Nursing home (NH) residents are at high risk for major bleeding and are frequently exposed to complex medication regimens that may increase the likelihood of clinically important drug–drug interactions (DDIs). However, DDI evidence from community‐dwelling populations may not generalize to NH residents, and real‐world signals involving ...
Adam M. D'Amico, Melissa R. Riester, Charles E. Leonard, Daniel A. Harris, Lori A. Daiello, Yu‐Chia (Sam) Hsu, Douglas P. Kiel, Meghan A. Cupp, Kaleen N. Hayes, Andrew R. Zullo   +9 more
wiley   +1 more source

How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives

, 2000
Brian L. Strom
openalex   +1 more source

Pharmacoepidemiology of hypolipidemic therapy in patients with metabolic syndrome in real clinical practice [PDF]

, 2018
Р. М. Магдеев, O. V. Reshetko
openalex   +1 more source

A Pharmaco‐Epidemiological Research Program Leveraging a Nationwide Database of Kidney Transplantation

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Objectives The pharmaco‐epidemiological research program in kidney transplantation (PERP‐KT) aims to evaluate, for the principal maintenance immunosuppressive drugs (MISDs): the influence of model‐informed precision dosing on graft and patient survival; long‐term exposure—effects relationships; and the benefit‐harm balance of their ...
Pierre Marquet, Antoine Humeau, Sabrina Crépin, Clément Benoist, Sylvain Couderc, Caroline Monchaud, Marc Labriffe, Franck Saint‐Marcoux   +7 more
wiley   +1 more source